http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1114021-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad3d51747a2eba1e7636894263252df4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C69-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P13-00 |
| filingDate | 1999-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c315341a41226dff5b2ab78d91cdffa |
| publicationDate | 2004-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1114021-B1 |
| titleOfInvention | NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS |
| abstract | Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The present invention relates to the new amine salts of HMG-CoA reductase inhibitors, the preparation thereof, the preparation of pure HMG-CoA reductase inhibitors via amine salts thereof, the use of the amine salts of HMG-CoA reductase inhibitors in the process for semisynthetic preparation of HMG-CoA reductase inhibitors, the use of the amine salts of HMG-CoA reductase inhibitors in the process for biotechnological modification of HMG-CoA reductase inhibitors as well as the conversion of the amine salts of HMG-CoA reductase inhibitors into the pharmaceutically acceptable salts of the HMG-CoA reductase inhibitors and the conversion of the amine salts of HMG-CoA reductase inhibitors into the HMG-CoA reductase inhibitors in the lactone form. |
| priorityDate | 1998-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 258.